Biotech Values

[ThomasS]

MNTA: Momenta Pharma can benefit from FDA rejection of Teva petition, says Oppenheimer
After the FDA rejected a petition from Teva (TEVA) to delay filings for generic versions of Copaxone, Oppenheimer believes the decision removes a roadblock to the approval of Momenta's (MNTA) generic version of the drug. The firm raised its target to $19 from $17 and maintains an Outperform rating